Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_assertion type Assertion NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_head.
- NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_assertion description "[Patients with interferon-associated type 1 diabetes retained higher levels of fasting serum C peptide as well as GAD65 antibodies than those with type 1A diabetes until 2 to 4 years after onset.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_provenance.
- NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_assertion evidence source_evidence_literature NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_provenance.
- NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_assertion SIO_000772 21270202 NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_provenance.
- NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_assertion wasDerivedFrom befree-2016 NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_provenance.
- NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_assertion wasGeneratedBy ECO_0000203 NP868016.RAelsYgGUeGCjP45ApStyLMqW-jS7AuuM4JBHONRlw6vE130_provenance.